Yuanda Pharmaceutical (00512) unveiled BIOHK2025 Go Global strategy to open up the global innovative drug market

The Zhitong Finance App learned that recently, the Hong Kong International Biotechnology Forum and Exhibition (BIOHK) was grandly opened in 2025. Many industry scientists, business leaders and investors gathered to discuss the future development of biotechnology. Yuanda Pharmaceutical (00512), an innovative international pharmaceutical company based on Hong Kong stocks, was invited to attend the conference and shared its experiences and thoughts on the global strategic layout of nuclear drugs with international peers during the Biotech Leaders Roundtable Forum on the theme of “Global Leaders Dialogue on the Future of Biomedicine”.

BIOHK2025 is a well-known biotechnology forum and exhibition in Asia. It has now become an important platform for industry insiders to exchange and discuss cutting-edge topics in the field of biotechnology. The conference is based in Hong Kong, an important hinterland where local Chinese enterprises have begun their internationalization journey, and provided support for the international development of many enterprises.

As a leading global nuclear drug company, Yuanda Pharmaceutical shared its unique global nuclear drug development strategy at this forum. With its global R&D, production and sales chain industrial layout, the company firmly implements the “Go Global” globalization strategy to promote the long-term release of the value of innovative products.

The benefits of the innovative strategy have been steadily realized, and the “China and US Double Report” is being promoted by looking at the global market

Against the backdrop of the release of the benefits of innovation and upgrading in the Chinese pharmaceutical industry, the global recognition of Chinese innovative drugs is constantly increasing. Relying on innovative drugs to seek more market space has also become one of the important choices for pharmaceutical companies. China Merchants Bank research shows that China's innovative drugs are going overseas at an accelerated pace. Take ASCO (American Society of Clinical Oncology), the largest event in the global cancer treatment field, as an example. The number of oral reports made by Chinese pharmaceutical companies in ASCO has grown from 25 in 2023 to 84 in 2025, and the amount of foreign authorized transactions for innovative drugs has exceeded the full year of 2024 since 2025, showing strong innovative strength.

As one of the benchmarks for the upgrading and development of Chinese pharmaceutical companies, Yuanda Pharmaceutical is relying on scientific and technological innovation to expand into a wider global market. The company's strong core competitiveness has also made it more relaxed and more long-term in terms of deploying innovative drugs overseas. Yuanda Pharmaceutical's “product globalization” and “industrial globalization” are advancing simultaneously. At present, it has taken the lead in achieving business breakthroughs in various aspects of nuclear drug R&D, production and sales overseas, laying a solid foundation for overseas localization.

In terms of products, Yuanda Pharmaceutical is continuously expanding the global market expansion of marketed drugs. Its innovative nuclear drug, Yigantai® Yttrium [90Y] microsphere injection, has been used by more than 150,000 people in more than 50 countries and regions. This product is the world's first and only selective internal radiation therapy product approved by the US FDA for the dual indications of unresectable HCC and colorectal cancer liver metastasis. Recently, the product was also approved for CE certification as a new indication in Europe. The scope of application is also approved for the treatment of liver cancer patients. On the basis of the original unresectable hepatocellular carcinoma (HCC) and unresectable colorectal cancer liver metastasis (mCRC), it extends to multiple indications such as unresectable intrahepatic cholangiocarcinoma (ICC), liver metastasis (MNet) due to neuroendocrine tumors, or other liver metastases. The classification of primary liver cancer and secondary liver metastases is more comprehensive, and the corresponding global market space is expected to double.

In terms of research and development, Yuanda Pharmaceutical focuses on the integrated treatment concept of cancer diagnosis and treatment. Currently, it has prepared 15 innovative products at the R&D registration stage, covering 5 types of radionuclides, including 68 Ga, 177 Lu, 131I, 90Y, and 89Zr, covering 8 types of cancer, including liver cancer, prostate cancer, kidney cancer, and brain cancer.

For drugs under development in the clinical research stage, the company has firmly promoted the “China and US double reporting” strategy. Various products such as the innovative radionuclide conjugate drug (RDC) TLX591 for treating prostate cancer and ITM-11, an innovative RDC drug for treating gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), have joined international multi-center phase III clinical research, laying the foundation for the company's innovative products to successfully obtain admission qualifications in many regions around the world. In fact, through years of global innovation, Yuanda Pharmaceutical can independently lead key R&D steps such as overseas research and development, clinical promotion, and registration applications for innovative products. This will also become an important advantage for the company to further promote overseas clinical research processes for innovative drugs.

In addition, many of the company's innovative products have also continued to appear at authoritative international conferences, further illuminating Yuanda Pharmaceutical's innovative drug brand. In 2025, two research abstracts of E-Gantai® were accepted by ASCO, and 15 research results were selected for the 2025 Asia-Pacific Expert Meeting on Primary Liver Cancer. In addition, the company's self-developed and innovative RDC drug GPN02006 also received an oral report from the North American Society of Nuclear Medicine and Molecular Imaging (SNMMI) in 2025.

The achievement of the internationalization of this series of innovative products indicates that the global layout driven by Yuanda Pharmaceutical's innovation has achieved results. With the firm implementation of the “Go Global” global strategic layout, in the future, Yuanda Pharmaceutical will accelerate innovation results with higher R&D efficiency to benefit the world, and will continue to enhance the influence and competitiveness of Chinese innovative drugs on the international stage with high standards of clinical data and product quality.

The full chain layout establishes an overseas advantage, and Go Global sets sail to create long-term growth

Supported by autonomous and controlled R&D bases and self-built production facilities, Yuanda Pharmaceuticals is developing globally. The company has now formed R&D bases with Boston and Chengdu as the core, production bases with Boston, Frankfurt, Singapore and Chengdu as the core, and has achieved a nuclear drug sales network covering more than 50 countries and regions around the world. It is the only international enterprise that has achieved full coverage of early nuclear drug research, clinical registration and commercialization.

In terms of production, Yuanda Pharmaceutical has improved the construction of production sites with the highest international standards to ensure a stable supply of global products, while product quality is also fully guaranteed. The company's Chengdu radiopharmaceutical R&D and production base, which was officially put into operation in June of this year, has established a world-class R&D and production quality and operation system. It is currently one of the smart factories with the most complete range of nuclides and the highest degree of automation in the world. It is also the world's first “zero radiation” intelligent nuclear drug factory and the world's first closed-loop platform for the entire nuclear drug industry chain.

In addition to the dominant field of nuclear drugs, Yuanda Pharmaceutical has carried out a global innovation layout in all of its major business segments. The company has laid out 5 R&D technology platforms and 8 R&D centers around the world, covering various business segments such as anti-tumor diagnosis and treatment of nuclear drugs, precise cardiovascular and cerebrovascular intervention, and pharmaceutical technology, and has reserved 133 research projects and 42 innovative projects, distributed at different stages from pre-clinical to new drug marketing applications, forming a good echelon effect.

This overseas localization layout, which runs through key chains such as R&D and production, not only allows Yuanda Pharmaceutical's innovative drugs to have multiple advantages in cost, efficiency, and compliance in international competition, but also enables them to deeply understand and respond to the unmet medical needs of patients around the world, laying an irreplaceable solid foundation for long-term roots in overseas markets.

As Yuanda Pharmaceuticals' “Go Global” overseas strategy continues to deepen in the future, while building its own pharmaceutical brand, the company will also achieve in-depth development and value exploration of the global market.